Predicting the in vivo mechanism of action for drug leads using NMR metabolomics

Steven Halouska, Robert J. Fenton, Raul G Barletta, Robert Powers

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

New strategies are needed to circumvent increasing outbreaks of resistant strains of pathogens and to expand the dwindling supply of effective antimicrobials. A common impediment to drug development is the lack of an easy approach to determine the in vivo mechanism of action and efficacy of novel drug leads. Toward this end, we describe an unbiased approach to predict in vivo mechanisms of action from NMR metabolomics data. Mycobacterium smegmatis, a non-pathogenic model organism for Mycobacterium tuberculosis, was treated with 12 known drugs and 3 chemical leads identified from a cell-based assay. NMR analysis of drug-induced changes to the M. smegmatis metabolome resulted in distinct clustering patterns correlating with in vivo drug activity. The clustering of novel chemical leads relative to known drugs provides a mean to identify a protein target or predict in vivo activity.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
JournalACS Chemical Biology
Volume7
Issue number1
DOIs
StatePublished - Jan 20 2012

Fingerprint

Metabolomics
Nuclear magnetic resonance
Pharmaceutical Preparations
Mycobacterium smegmatis
Cluster Analysis
Metabolome
Pathogens
Mycobacterium tuberculosis
Disease Outbreaks
Assays
Proteins

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Predicting the in vivo mechanism of action for drug leads using NMR metabolomics. / Halouska, Steven; Fenton, Robert J.; Barletta, Raul G; Powers, Robert.

In: ACS Chemical Biology, Vol. 7, No. 1, 20.01.2012, p. 166-171.

Research output: Contribution to journalArticle

@article{4163dff04e2e4b218ed1c81d9b4ec042,
title = "Predicting the in vivo mechanism of action for drug leads using NMR metabolomics",
abstract = "New strategies are needed to circumvent increasing outbreaks of resistant strains of pathogens and to expand the dwindling supply of effective antimicrobials. A common impediment to drug development is the lack of an easy approach to determine the in vivo mechanism of action and efficacy of novel drug leads. Toward this end, we describe an unbiased approach to predict in vivo mechanisms of action from NMR metabolomics data. Mycobacterium smegmatis, a non-pathogenic model organism for Mycobacterium tuberculosis, was treated with 12 known drugs and 3 chemical leads identified from a cell-based assay. NMR analysis of drug-induced changes to the M. smegmatis metabolome resulted in distinct clustering patterns correlating with in vivo drug activity. The clustering of novel chemical leads relative to known drugs provides a mean to identify a protein target or predict in vivo activity.",
author = "Steven Halouska and Fenton, {Robert J.} and Barletta, {Raul G} and Robert Powers",
year = "2012",
month = "1",
day = "20",
doi = "10.1021/cb200348m",
language = "English (US)",
volume = "7",
pages = "166--171",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Predicting the in vivo mechanism of action for drug leads using NMR metabolomics

AU - Halouska, Steven

AU - Fenton, Robert J.

AU - Barletta, Raul G

AU - Powers, Robert

PY - 2012/1/20

Y1 - 2012/1/20

N2 - New strategies are needed to circumvent increasing outbreaks of resistant strains of pathogens and to expand the dwindling supply of effective antimicrobials. A common impediment to drug development is the lack of an easy approach to determine the in vivo mechanism of action and efficacy of novel drug leads. Toward this end, we describe an unbiased approach to predict in vivo mechanisms of action from NMR metabolomics data. Mycobacterium smegmatis, a non-pathogenic model organism for Mycobacterium tuberculosis, was treated with 12 known drugs and 3 chemical leads identified from a cell-based assay. NMR analysis of drug-induced changes to the M. smegmatis metabolome resulted in distinct clustering patterns correlating with in vivo drug activity. The clustering of novel chemical leads relative to known drugs provides a mean to identify a protein target or predict in vivo activity.

AB - New strategies are needed to circumvent increasing outbreaks of resistant strains of pathogens and to expand the dwindling supply of effective antimicrobials. A common impediment to drug development is the lack of an easy approach to determine the in vivo mechanism of action and efficacy of novel drug leads. Toward this end, we describe an unbiased approach to predict in vivo mechanisms of action from NMR metabolomics data. Mycobacterium smegmatis, a non-pathogenic model organism for Mycobacterium tuberculosis, was treated with 12 known drugs and 3 chemical leads identified from a cell-based assay. NMR analysis of drug-induced changes to the M. smegmatis metabolome resulted in distinct clustering patterns correlating with in vivo drug activity. The clustering of novel chemical leads relative to known drugs provides a mean to identify a protein target or predict in vivo activity.

UR - http://www.scopus.com/inward/record.url?scp=84856162572&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856162572&partnerID=8YFLogxK

U2 - 10.1021/cb200348m

DO - 10.1021/cb200348m

M3 - Article

C2 - 22007661

AN - SCOPUS:84856162572

VL - 7

SP - 166

EP - 171

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 1

ER -